Table 3.
Age stratified analysis on gender distribution, symptoms and fatalities of nationwide patients with COVID-19 in Bangladesh.
| Variables |
Age groups in years (%) |
P value |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0–9 |
10–19 |
20–29 |
30–39 |
40–49 |
50–59 |
60–69 |
>70 |
|||
| Total number | 5 | 51 | 319 | 205 | 161 | 139 | 63 | 23 | .041 | |
| Sex | Male | 2 (40%) | 24 (47.1%) | 214 (67.1%) | 143 (69.8%) | 99 (61.5%) | 89 (64%) | 47 (74.6%) | 18 (78.3%) | .003 |
| Female | 3 (60%) | 27 (52.9%) | 105 (32.9%) | 62 (30.2%) | 62 (38.5%) | 50 (36%) | 16 (25.4%) | 5 (21.7%) | .014 | |
| Duration of symptoms | 7–14 days | 5 (100%) | 36 (70.6%) | 219 (68.7%) | 98 (47.8%) | 82 (50.9%) | 68 (48.9%) | 30 (47.6%) | 10 (43.5%) | .001 |
| 15–28 days | 0 (0%) | 10 (19.6%) | 92 (28.8%) | 96 (46.8%) | 69 (42.9%) | 55 (39.6%) | 25 (39.7%) | 10 (43.5%) | .005 | |
| 1–2 months | 0 (0%) | 4 (7.8%) | 8 (2.5%) | 8 (3.9%) | 10 (6.2%) | 14 (10.1%) | 8 (12.7%) | 3 (13%) | .012 | |
| > 2 months | 0 (0%) | 1 (2%) | 0 (0%) | 3 (1.5%) | 0 (0%) | 2 (1.4%) | 0 (0%) | 0 (0%) | .034 | |
| Comorbidities (before COVID-19) | Yes | 0 (0%) | 11 (21.6%) | 50 (15.7%) | 31 (15.1%) | 65 (40.4%) | 61 (43.9%) | 37 (58.7%) | 16 (69.6%) | .001 |
| No | 5 (100%) | 40 (78.4%) | 269 (84.3%) | 174 (84.9%) | 96 (59.6%) | 78 (56.1%) | 26 (41.3%) | 7 (30.4%) | .017 | |
| Comorbidities (after COVID-19) | Yes | 0 (0%) | 6 (11.8%) | 41 (12.9%) | 20 (9.8%) | 23 (14.3%) | 33 (23.7%) | 16 (25.4%) | 7 (30.4%) | .043 |
| No | 5 (100%) | 45 (88.2%) | 278 (87.1%) | 185 (90.2%) | 138 (85.7%) | 106 (76.3%) | 47 (74.6%) | 16 (69.6%) | .022 | |
| Symptoms of other disease increased after COVID-19 infection | Yes | 0 (0%) | 8 (15.7%) | 64 (20.1%) | 56 (27.3%) | 59 (36.6%) | 58 (41.7%) | 23 (36.5%) | 10 (43.5%) | .005 |
| No | 5 (100%) | 43 (84.3%) | 255 (79.9%) | 149 (72.7%) | 102 (63.4%) | 81 (58.3%) | 40 (63.5%) | 13 (56.5%) | .049 | |
| Treatment problems during COVID-19 | Yes | 0 (0%) | 11 (21.6%) | 60 (18.8%) | 33 (16.1%) | 27 (16.8%) | 45 (32.4%) | 14 (22.2%) | 8 (34.8%) | .019 |
| No | 5 (100%) | 40 (78.4%) | 259 (81.2%) | 172 (83.9%) | 134 (83.2%) | 94 (67.6%) | 49 (77.8%) | 15 (65.2%) | .348 | |
| Death due to COVID-19 | Yes | 0 (0%) | 2 (3.9%) | 22 (6.9%) | 4 (2%) | 11 (6.8%) | 25 (18%) | 23 (36.5%) | 14 (60.9%) | .002 |
| No | 5 (100%) | 49 (96.1%) | 297 (93.1%) | 201 (98%) | 150 (93.2%) | 114 (82%) | 40 (63.5%) | 9 (39.1%) | .043 | |